Business Context and Reporting Period
This Form 8-K Current Report from DarioHealth Corp. covers events occurring between February 28, 2018, and March 6, 2018. The filing details the execution of Securities Purchase Agreements for a concurrent placement offering of equity securities to accredited and non-U.S. investors.
Key Financial Metrics and Transaction Details
The filing describes a capital raise rather than operational financial results. Key transaction metrics include:
- Common Stock Issued: 2,262,269 shares at $1.40 per share.
- Series C Preferred Stock Issued: 1,234,080 shares at $2.80 per share.
- Warrants Issued: Warrants to purchase up to 3,784,351 shares of Common Stock at an exercise price of $1.80 per share.
- Consulting Fees: Aggregate cash fee of $538,000 plus issuance of 32,250 shares of Common Stock and 18,920 warrants to consultants.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Governance
Material changes resulting from this filing include:
- Capital Structure: Designation and issuance of Series C Convertible Preferred Stock, convertible into 2,468,160 shares of Common Stock at $1.40 per share upon stockholder approval.
- Board Composition: A significant investor was granted the right to appoint one individual to the Board of Directors, contingent on maintaining ownership of over 5% of outstanding Common Stock.
- Liquidity Restrictions: The significant investor agreed to a 90-day lock-up period on securities disposal.
- Registration Obligation: The Company agreed to file a registration statement for the resale of securities by April 30, 2018.
Outlook, Risks, and Contingencies
The filing includes a standard cautionary note regarding forward-looking statements, noting that actual results may differ materially due to various risks. Specific contingencies include:
- Conversion Conditions: Series C Preferred Stock cannot be converted to Common Stock until stockholder approval is obtained.
- Warrant Terms: Warrants are exercisable only after a six-month anniversary and expire on the eighteen-month anniversary. They include anti-dilution protections and cashless exercise options if registration is not effective.
- Liquidation Preference: Series C holders have a liquidation preference equal to their investment in certain deemed liquidation events, such as a change in control.
Investor Verification Checklist
- Verify the total gross proceeds raised from the offering based on the share counts and prices listed.
- Confirm the timeline for the required registration statement filing (due April 30, 2018).
- Monitor the status of stockholder approval required for the conversion of Series C Preferred Stock.
- Review the impact of the new Board member appointment on corporate governance.
- Assess the dilution impact of the 3,784,351 warrant shares and the 32,250 consultant shares.